Enspryng (satralizumab-mwge) | Neuromyelitis News
Enspryng (satralizumab-mwge) is an injection therapy approved for adults with neuromyelitis optica spectrum disorder (NMOSD).| Neuromyelitis News
While neuromyelitis optica spectrum disorder's causes are not fully understood, self-reactive antibodies against AQP4 are known major drivers.| Neuromyelitis News
Enspryng (satralizumab-mwge) is an injection therapy approved for adults with neuromyelitis optica spectrum disorder (NMOSD).| Neuromyelitis News
Neuromyelitis optica spectrum disorder affects the optic nerve, spinal cord, and sometimes the brainstem, resulting in a number of symptoms.| Neuromyelitis News
Category archive page for News.| Neuromyelitis News
Steve Bryson is a science writer for Neuromyelitis News with a PhD in biochemistry. He covers the latest news and information on a variety of NMO topics.| Neuromyelitis News
In patients treated with Enspryng, researchers found the proportions of B-cells was unchanged, suggesting it altered their characteristics.| Neuromyelitis News
